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Immune responseThe protective capacities of a native double-domain activation-associated secreted protein (ndd-ASP)-
based vaccine against the cattle intestinal nematode Cooperia oncophora has previously been demon-
strated. However, protection analysis upon vaccination with a recombinantly produced antigen has never
been performed. Therefore, the aim of the current study was to test the protective potential of a Pichia-
produced double-domain ASP (pdd-ASP)-based vaccine against C. oncophora. Additionally, we aimed to
compare the cellular and humoral mechanisms underlying the vaccine-induced responses by the native
(ndd-ASP) and recombinant vaccines. Immunisation of cattle with the native C. oncophora vaccine con-
ferred significant levels of protection after an experimental challenge infection, whereas the recombinant
vaccine did not. Moreover, vaccination with ndd-ASP resulted in a higher proliferation of CD4-T cells both
systemically and in the small intestinal mucosa when compared with animals vaccinated with the
recombinant antigen. In terms of humoral response, although both native and recombinant vaccines
induced similar levels of antibodies, animals vaccinated with the native vaccine were able to raise anti-
bodies with greater specificity towards ndd-ASP in comparison with antibodies raised by vaccination
with the recombinant vaccine, suggesting a differential immune recognition towards the ndd-ASP and
pdd-ASP. Finally, the observation that animals displaying antibodies with higher percentages of recogni-
tion towards ndd-ASP also exhibited the lowest egg counts suggests a potential relationship between
antibody specificity and protection.
 2017 The Author(s). Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The economic impact of gastrointestinal nematode infections in
ruminants has been extensively demonstrated over the years
(Charlier et al., 2014). To date, control of these infections in live-
stock relies almost exclusively on the use of anthelminthic drugs,
but the increasing spread of anthelmintic resistance worldwide
illustrates the need for alternative control strategies (De Graef
et al., 2013; Geurden et al., 2015). Successful vaccination against
gastrointestinal nematodes with native and recombinant proteins
in cattle and sheep (Meyvis et al., 2007; Besier et al., 2012;
Nisbet et al., 2013; Vlaminck et al., 2015; Gonzalez-Hernandez
et al., 2016), demonstrates that protein-based vaccination is apromising alternative to the current control methods (Matthews
et al., 2016). Recently, our group has shown that vaccination with
native double-domain activation-associated secreted protein (ndd-
ASP) obtained from the excretory-secretory material of the adult
stages of the bovine intestinal nematode Cooperia oncophora
(Borloo et al., 2013) provides protection both under experimental
and natural conditions, as indicated by a decrease in the cumula-
tive egg output of 91% and 59%, respectively (Vlaminck et al.,
2015). Under natural conditions, vaccination of cattle with the
ndd-ASP also resulted in a 65% reduction in pasture larval counts
and a decrease in 82% of worm counts when compared with the
control group (Vlaminck et al., 2015). Additional studies on the
immune response elicited by vaccination with ndd-ASP have
shown an increased antigen-specific antibody production, which
correlated negatively with the egg output. Moreover, significant
T-cell proliferation was induced in ndd-ASP vaccinated animals
after in vitro stimulation with the antigen, which was positively
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Meulder et al., 2015). Despite these promising results achieved
with the native antigen, recombinant production of the antigen
would be an absolute requirement for the economic viability of
the vaccine (Geldhof et al., 2007; Matthews et al., 2016). Therefore,
the objectives of the present study were: (i) to produce and evalu-
ate the protective capacity of a Pichia-produced version of the dd-
ASP, and (ii) to compare the cellular and humoral responses
induced by both native and recombinant versions of the antigen.2. Materials and methods
2.1. Native and recombinant antigen production
Preparation of the native C. oncophora dd-ASP (ndd-ASP) was
carried out as previously described (Borloo et al., 2013a). In short,
excretory-secretory material of adult worms was collected and
fractionated over a Superdex 200 16/70 size-exclusion chromatog-
raphy column. The purity of the ndd-ASP fraction, which eluted
first from the column, was checked by reducing and non-
reducing one-dimensional gel electrophoresis (SDS–PAGE) and
visualized by Simply-Blue SafeStain (Invitrogen, USA) staining.
Afterwards, the protein band was excised and protein identity
was further confirmed by mass spectrometry.
Recombinant double-domain ASP (pdd-ASP) was expressed in
Pichia pastoris as follows: its coding sequence (Borloo et al.,
2013b) was PCR-amplified and subsequently cloned into the
pGEMt-Easy subcloning vector (Promega, USA) according to the
manufacturer’s instructions. Following transformation into Escher-
ichia coli DH5a competent cells (Invitrogen), clone selection on X-
gal plates and sequence verification, the pGEMt-Easy-nDD-ASP
construct was linearized by EcoRI-XbaI digestion and inserted in
the Pichia expression vector pPICZa B (Thermo Fischer Scientific,
USA). The resulting expression plasmid was used to transform P.
pastoris strain KM071H (Invitrogen) by electroporation. After-
wards, individual clones growing on minimal plates were isolated
and tested for secretion of pdd-ASP by SDS–PAGE followed by Coo-
massie Brilliant Blue staining and immunoblotting with bovine-
anti-ndd-ASP antibodies. A clone expressing pdd-ASP was freshly
grown on minimal plates and then used to inoculate a shake flask
culture with buffer minimal glycerol complex medium (BMGY).
After 48 h of growth at 29 C, the cells were pelleted by centrifuga-
tion for 15 min at 1,000g followed by resuspension of the cells in
buffered methanol complex medium (BMMY) and further growth
at 29 C. Every 24 h, extra methanol (0.5%) was added to the cul-
ture and after 96 h of induction the cells were finally pelleted by
centrifugation for 15 min at 2,000g. The cell medium was har-
vested and filtered over a 0.22 lm membrane, after which the
supernatant was concentrated on a Centriprep YM10 (Millipore,
USA), dialyzed to 50 mM sodium acetate pH 5.0 and desalted on
a HiPrep 26/10 Desalting column (GE Healthcare Bio-Sciences,
USA). This fraction was then applied to a Resource-S cation
exchange column (GE Healthcare Bio-Sciences AB) equilibrated in
50 mM sodium acetate buffer (pH 5.0) and the bound pdd-ASP
was eluted by employing a gradient from 0 up to 1 M sodium chlo-
ride (NaCl) in the same buffer. Fractions containing pdd-ASP were
pooled and buffer-exchanged to PBS by gel filtration on a Sephadex
G25-column (GE Healthcare Bio-Sciences). The protein profile of
the obtained material was checked on a 12% reducing SDS–PAGE.
Additionally, ndd- and pdd-ASP proteins were blotted onto a
poly-vinylidene fluoride (PVDF) membrane for 1 h at 1 mA/cm2
of gel surface followed by a 1 h blocking step in PBS +0.5% Tween80
(PBST). The membrane was afterwards incubated with ndd-ASP-
specific antibodies (dilution 1/500) for 1 h, followed by extensive
washing with PBST and incubation for 1 h with horseradishperoxidase (HRP)-conjugated rabbit anti-bovine IgG1 antibody.
3,30-diaminobenzidine (DAB) (Sigma–Aldrich, USA) served as a
substrate. All steps were performed at room temperature.
2.2. Immunization experiments in cattle
All animal experiments were conducted in accordance with the
European Union Animal Welfare Directives and VICH (Interna-
tional Cooperation on Harmonisation of Technical Requirements
for Registration of Veterinary Medicinal Products) guidelines for
Good Clinical Practice, and ethical approvals to conduct the studies
were obtained from the Ethical Committee of the Faculty of Veteri-
nary Medicine, Ghent University, Belgium (EC2014/70,
EC2015/40). Two vaccination studies were carried out in cattle as
previously described (Van Meulder et al., 2015; Vlaminck et al.,
2015).
The aim of study 1 was to investigate the protective capacity of
the recombinant antigen. Twenty-one helminth-naïve male cross-
breed Holstein calves (6–8 months of age) were randomly divided
over three groups of seven animals (QuilA control, ndd-ASP+QuilA
and pdd-ASP+QuilA). Subsequently, a second study was performed
to analyse and compare the cellular responses induced by the
native and recombinant antigens, where 12 helminth-naïve female
crossbreed Holstein calves (6–8 months of age) were randomly
divided over three groups of four animals (QuilA control, ndd-
ASP+QuilA and pdd-ASP+QuilA). For both studies, all animals were
immunized three times i.m. in the neck at 3 week intervals. Control
animals received 750 lg of QuilA (Superfos Biosector, USA), while
the animals in the ndd-ASP+QuilA and pdd-ASP+QuilA groups
received 30 lg of antigen in combination with 750 lg of QuilA
per immunization. All animals were challenged with a trickle
infection of 25,000 L3s (1000 L3s/day; 5 days/week for 5 weeks),
which started on the day of the third immunization, and were then
euthanized 3 weeks after the last infection. Parasitological param-
eters (i.e. faecal egg and worm counts) were monitored as previ-
ously described (Van Meulder et al., 2015; Vlaminck et al., 2015).
2.3. Isolation of peripheral blood mononuclear cells (PBMCs)
In Study 2, blood samples were collected weekly from the jugu-
lar vein using vacutainer tubes. PBMCs were isolated by Lympho-
prep (Nycomed Pharma, Norway) gradient centrifugation.
Additionally, mesenteric lymph nodes (LNs) of the small intestine
were isolated at the time of necropsy, and LN mononuclear cells
(MNCs) were isolated by homogenization through mechanical dis-
ruption of the tissue followed by Lymphoprep gradient centrifuga-
tion. After centrifugation, all mononuclear cell fractions were
isolated, washed and counted prior to cell culture and flow cyto-
metric analysis.
2.4. Flow cytometry
Cells were labelled in Flow Cytometry Staining Buffer (eBio-
science, USA) and all antibodies were used at the concentration
recommended by the supplier. After incubation for 20 min with
primary antibodies, the cells were washed twice prior to staining
with fluorescently-labelled secondary antibodies. The cells were
then incubated for an additional 20 min, washed and resuspended
in PBS to be immediately analysed using a FACS Aria III flow
cytometer (BD Biosciences, USA). Non-viable cells were excluded
from the analysis based on their propidium iodide (Life Technolo-
gies, USA) uptake.
Primary antibodies used were: non-labeled CD3 (MM1A, IgG1),
TCRcd (GB21A, IgG2b), CD21 (BAQ15A, IgM), CD8 (BAQ111A, IgM)
(all from Monoclonal Antibody Center, Washington University,
USA), CD4 (CC8, IgG2a) and CD335-IgG2b (AKS6, IgG1, kindly
A. González-Hernández et al. / International Journal for Parasitology 48 (2018) 41–49 43provided by Prof. Dr. Anne K. Storset, Faculty of Veterinary Medi-
cine of Oslo, Norway). Secondary antibodies used were: goat
anti-mouse IgG1-V450 (BD Biosciences, USA), goat anti-mouse
IgG2a-APC (Invitrogen), rat anti-mouse IgG2b-FITC (Southern Bio-
tech, USA) and rat anti-mouse IgM-APC-Cy7 (Biolegend, USA).
2.5. Proliferation assays
The PBMCs and MNCs collected from blood and mesenteric LNs,
respectively, in study 2 were used in proliferation assays using
either 3H-thymidine (3HT) incorporation or PKH26 (Sigma–Aldrich,
USA) fluorescence intensity reduction as a read-out as previously
described (Gonzalez-Hernandez et al., 2016). For the 3HT uptake
experiments, cells were seeded at 1.25  106 cells/ml in a 96-well
round-bottom plate (Thermo Scientific, USA) in complete medium
(RPMI 1640 + GlutaMAX (Invitrogen, USA), 50 lg/ml of Gen-
tamycin (Invitrogen, USA), 50 lM b-mercaptoethanol (Sigma–
Aldrich, USA) and 10% FCS (Moregate, Australia)). Each well was
either stimulated with medium alone, 5 lg/ml of ndd-ASP, 5 lg/
ml of pdd-ASP or 1 lg/ml of ConA (Sigma–Aldrich, USA). Five days
later, cells were pulsed with 1 lCi 3HT (Perkin Elmer, USA). After
18 h, cells were harvested and analysed with a 1450 Microbeta
b-scintillation counter (Perkin Elmer).
For the Paul Karl Horan (PKH)26 experiments, PBMCs and
mesenteric LN MNCs were collected 1 week after the last vaccina-
tion and at the time of necropsy, respectively, and labelled with
PKH26 (Sigma–Aldrich, USA) as previously described (Gonzalez-
Hernandez et al., 2016). After labelling, cells were seeded at
2.5  106 cells/ml in complete medium in 96-well round-bottom
plates, and either stimulated with medium alone, 5 lg/ml of
ndd-ASP or 5 lg/ml of pdd-ASP. After 5 days of culture, the cells
were harvested, stained with monoclonal antibodies and analysed
by flow cytometry. ModFit LT software (Verity Software House)
was used to calculate the proliferation index (PI) for the different
cell populations.
In order to measure cytokine production during the prolifera-
tion of bovine PBMCs and mesenteric LN MNCs, supernatants of
the abovementioned cultures were collected at time of harvesting
after 5 days of culture. ELISA for detection of IFNc and IL-4 was
performed by coating capture monoclonal antibodies in carbonate
buffer (pH 9.6) on 96-well Maxisorp (Nunc, USA) plates at a con-
centration of 2 lg/ml and 4 lg/ml, respectively. Plates were incu-
bated with blocking buffer (2% BSA in PBS supplemented with
0.05% Tween20 (Sigma–Aldrich)) for 1 h. Afterwards, 25 ll or
50 ll of supernatant (for detection of IFNc and IL-4, respectively)
were placed in each well and blocking buffer was used to adjust
the volume to 100 ll per well. Biotinylated monoclonal antibodies
raised against IFNc or IL-4 were added at 2 lg/ml. Streptavidin–
HRP (Sigma–Aldrich, USA) was used as a conjugate and 3,30,5,50
tetramethylbenzidine (TMB) (Thermo Scientific, USA) served as
substrate. OD was measured at 450 nm. All antibodies were kindly
provided by Prof. Jayne Hope (The Roslin Institute, UK).
2.6. Antibody responses
For both studies, sera were collected before the first immunisa-
tion and 1 week after each immunisation. In addition, a 1 cm2 piece
of the small intestine (complete intestinal wall) at 3 m from the
pylorus was collected at the time of necropsy. Small intestinal
extracts were obtained by incubating ground frozen tissue in PBS
for 2 h at 4 while shaking, and the protein concentration was
determined with a bicinchoninic acid (BCA) assay kit (Pierce,
USA). Samples were subsequently centrifuged for 15 min at
16000g and the supernatants collected.The systemic and intestinal IgG1, IgG2 and IgA levels against the
C. oncophora ndd-ASP were then determined by ELISA. ndd-ASP
was coated on 96-well Maxisorp plates (Nunc, USA) at a concentra-
tion of 0.5 lg/ml in carbonate buffer (pH 9.6). After 1 h incubation
with blocking buffer (2% BSA-PBS-0.05%Tween20), either 100 lg of
intestinal extract or 100 ll of serum, 1/200-diluted in blocking buf-
fer, were added in duplicate and incubated for an additional hour.
After washing, sheep anti-bovine IgG1, IgG2 and IgA (Bio-Rad, USA)
coupled to horseradish peroxidase (HRP) were used as conjugates
(dilution 1/500). 2,20-azino-bis(3-ethylbenzothiazoline-6-sulpho
nic acid) (ABTS) (Roche, Switzerland) served as a substrate. The
OD was measured at 405 nm with a reference wavelength at
492 nm.
In addition, inhibition ELISA (iELISA) assays were performed to
evaluate and compare the specificity of the antibodies raised
against the native and recombinant versions of the dd-ASP. For
both studies, pooled small intestinal extracts from the ndd-ASP
+QuilA vaccinated animals were incubated at a final concentration
of 200 lg/ml for 1 h at room temperature with different concentra-
tions of either ndd-ASP or pdd-ASP, ranging from 0 to 1000 pmol/
ml. The pre-incubated samples were afterwards tested in duplicate
in a ndd-ASP coated plate as previously described for the conven-
tional ELISA. Finally, an additional iELISA for the IgG1 isotype was
performed for study 2 where intestinal extract from ndd-ASP
+QuilA vaccinated animals was pre-incubated with pdd-ASP, and
tested afterwards on a a ndd-ASP coated plate as described for
the conventional ELISA.
2.7. Statistical analysis
Statistical analyses were carried out using GraphPad Prism soft-
ware. A non-parametric Kruskal–Wallis test followed by a Dunn’s
multiple comparison test were used to determine significant dif-
ferences in parasitological parameters, antibody responses and
3HT assays. For the latter, an additional Analysis of Covariance
(ANCOVA) (SPSS, IBM SPSS statistics version 23.0) was used to
evaluate the impact of the outcome of one specific week in the
results of the consecutive week. To determine significant differ-
ences in cytokine production and proliferation between the various
cell subsets in the PBMCs and MNCs, a non-parametric Mann–
Whitney test was used. P 0.05 was considered significant.
3. Results
3.1. Evaluation of a C. oncophora recombinant-ASP protein as a
potential vaccine candidate
Following expression and purification of the pdd-ASP, the cor-
rect size and purity of the protein was verified by SDS–PAGE anal-
ysis (Supplementary Fig. S1), showing uniform glycosylation in
contrast to its native counterpart which displays more heterogene-
ity in its N-glycan profile. Afterwards, the protein band was excised
and the protein identity was further confirmed by mass spectrom-
etry (data not shown).
This material was subsequently used in a first study to evaluate
the protective capacities of the recombinantly produced C. onco-
phora dd-ASP protein in comparison with the native antigen. As
indicated in Fig. 1, animals vaccinated with the ndd-ASP+QuilA
vaccine showed a reduction of 99% in cumulative faecal egg counts
(cumFEC) and 88% decrease in worm counts compared with the
control vaccinated group, confirming previous findings (Vlaminck
et al., 2015). Lower cumFEC and worm counts were observed fol-
lowing vaccination with pdd-ASP+QuilA, although differences did
not reach statistical significance (Fig. 1A and B).
Fig. 1. Effect of vaccination with native (n) versus recombinant (p) double-domain activation-associated secreted protein (dd-ASP) of Cooperia oncophora on egg and worm
counts. For animals vaccinated with QuilA alone (Control), ndd-ASP+QuilA and pdd-ASP+QuilA, (A) cumulative number of eggs per gram of faeces (cumFEC) and (B) worm
counts in Study 1 were determined three times each week during the trickle infection and at the time of necropsy, respectively. Graphs show the mean cumFEC or worm
counts in each group ± S.E.M. Statistically significant differences compared with control vaccinated animals are indicated with *(P  0.05), **(P  0.005), ***(P  0.001).
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versions of the vaccine
Vaccination with both ndd-ASP+QuilA and pdd-ASP+QuilA vac-
cines resulted in a significant increase in ndd-ASP-specific IgG1
and IgG2 levels in sera compared with QuilA control animals, while
a significant increase in systemic IgA levels could only be detected
after vaccination with ndd-ASP+QuilA (Fig. 2A). In the small
intestinal mucosa, vaccination with the ndd-ASP+QuilA vaccine
also resulted in a significant increase in ndd-ASP-specific IgA,
IgG1 and IgG2 levels, whereas vaccination with pdd-ASP+QuilA
only induced a significant increase in the ndd-ASP-specific IgG2
level, and higher but not significant levels of IgG1 or IgA (Fig. 2B).
To determine possible differences in the specificity of antibod-
ies induced by vaccination with ndd-ASP+QuilA, pooled small
intestinal extracts collected at necropsy were subjected to an
iELISA. Pre-incubation of the small intestinal extracts with pdd-
ASP failed to inhibit the binding of the IgG1, IgG2 and IgA antibod-
ies induced in ndd-ASP+QuilA vaccinated animals, while pre-
incubation with ndd-ASP almost completely inhibited IgG1, IgG2
and IgA binding to ndd-ASP (Fig. 2C).
3.3. Analysis and comparison of the cellular vaccine-induced responses
by the native and recombinant vaccines
The aim of the second study was to confirm the results obtained
in study 1 in terms of antibody responses, and to compare the dif-
ferences in the vaccine-induced cellular responses between both
native and recombinant vaccines. To do so, an experimental design
similar to study 1 was carried out where animals were challenged
post-vaccination and cellular, humoral and parasitological param-
eters were monitored.
To monitor cellular responses during the vaccination period,
PBMCs were isolated on a weekly basis to measure antigen-
specific proliferation in vitro. Results are shown in Fig. 3A as a
stimulation index (SI) (= counts per minute (CPM) antigen stimu-
lated cells/CPM medium stimulated cells). After in vitro restimula-
tion of PBMCs with the vaccine antigens (ndd-ASP for the ndd-ASP
+QuilA and Control groups, and pdd-ASP for the pdd-ASP+QuilA)
antigen-specific proliferation was found in the ndd-ASP+QuilA
group (Fig. 3A). Proliferation in the ndd-ASP+QuilA group was the
highest and significantly different from control animals at week
4 after the first vaccination. From week 5 onwards, cellular prolif-eration continued to be significantly higher in the ndd-ASP+QuilA
group compared with control and pdd-ASP-vaccinated animals.
One week after the third vaccination (week 7), vaccine antigen-
specific proliferation could also be observed in animals vaccinated
with pdd-ASP+QuilA (Fig. 3A). Additionally, an ANCOVA test was
performed to assess the potential effect of the results of one week
in the following week with no significant results.
To determine the phenotype of the antigen-specific PBMCs that
proliferated during the vaccination period after in vitro stimula-
tion, PBMCs were isolated at week 7, labelled with PKH and cul-
tured either in the presence of medium alone or 5 lg/ml of the
vaccine antigen. After 5 days, cells from all groups were harvested
and analysed by flow cytometry. Although the thymidine data
showed antigen-specific proliferation at week 7 in the pdd-ASP
+QuilA group, no proliferating cell population could be identified
in the PKH assay (Fig. 3B and C). Whether this is due to a popula-
tion of cells for which no specific markers were included in the PKH
assay is currently unclear. On the other hand, significant antigen-
specific proliferation of CD4-T cells after in vitro stimulation with
ndd-ASP was observed in animals vaccinated with ndd-ASP
+QuilA when compared with the medium-stimulated cells
(Fig. 3D).
To characterize the phenotype of the cellular response in the
small intestine following vaccination and challenge infection, LNs
from all animals were collected at time of necropsy and MNCs
were stimulated in vitro as previously described for PBMCs. For
all groups, proliferation of cd-T cells, CD4-Tcells, natural killer
(NK) cells and non-T, non-B non-NK cells (CD3-/CD21-/CD335-)
was significantly higher after re-stimulation with ndd-ASP
(Fig. 4A–C), suggesting that the challenge infection had an effect
on the local immune response. However, proliferation after re-
stimulation with ndd-ASP was significantly higher in animals vac-
cinated with ndd-ASP+QuilA for CD4-T cells and CD8-T cells when
compared with the control and pdd-ASP+QuilA groups (Fig. 4D).
ELISAs performed to detect the presence of either IL-4 or IFNc in
the culture supernatants showed that in vitro restimulation with
ndd-ASP induced a significantly higher production of both IL-4
and IFNc in all groups when compared with the medium stimu-
lated cells (Fig. 4E and F).
Identical to study 1, the systemic and mucosal antibody
responses were measured both in a quantitative and qualitative
way. The levels of IgG1 and IgG2, but not of IgA, ndd-ASP-
specific antibodies in serum were significantly higher in animals
Fig. 2. Antibody responses in serum and mucosa after vaccination with the native and recombinant vaccines. In cattle study 1, (A) serum from 1 week after the second
vaccination and (B) mucosal samples were collected from all animals and used for the detection of Cooperia oncophora native double-domain activation-associated secreted
protein (ndd-ASP)-specific IgG1, IgG2 and IgA antibodies by ELISA. The graphs show the individual absorbance values within each group and the mean ± S.E.M. Statistically
significant differences are indicated with *(P  0.05), **(P  0.005), ***(P  0.001). (C) Small intestinal extracts from calves vaccinated with ndd-ASP+QuilA were pre-incubated
with either ndd-ASP or recombinant (p)dd-ASP and evaluated in an inhibition ELISA for IgG1, IgG2 and IgA isotypes. Graphs were generated from pooled samples analysed in
duplicate.
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mentary Fig. S2A). In the mucosa, IgG1 levels were significantly
higher in ndd-ASP+QuilA vaccinated animals but not in pdd-ASP
+QuilA vaccinated animals (Supplementary Fig. S2B). In contrast,
animals vaccinated with pdd-ASP+QuilA showed a significant
increase in antigen-specific IgG2 and IgA levels. This increase,
although not significant, could also be observed in animals vacci-
nated with ndd-ASP+QuilA (Supplementary Fig. S2B). Finally, iELI-
SAs for IgG1, IgG2 and IgA were performed with intestinal
extracts from animals vaccinated with ndd-ASP+QuilA with iden-
tical results to those observed in Study 1 (Supplementary
Fig. S2C).
Finally, in terms of parasitological parameters, no reduction
could be observed for animals vaccinated with pdd-ASP+QuilA
(Supplementary Fig. S3). On the other hand, three out of four ani-
mals in the ndd-ASP+QuilA group did show a clear reduction in
cumEPG (Supplementary Fig. S3A) but, importantly, one animalwas not protected. In order to investigate whether there was a cor-
relation between antibody specificity and protection, an IgG1
iELISA was performed on intestinal extract from the individual ani-
mals vaccinated with ndd-ASP+QuilA, in which the extracts were
pre-incubated with pdd-ASP and subsequently tested for binding
a ndd-ASP coated plate. Ideally, pdd-ASP would be able to display
similar inhibitory capacities towards antibodies as the ndd-ASP,
and pre-incubation of antibodies from ndd-ASP-vaccinated ani-
mals with pdd-ASP should prevent them from binding the ndd-
ASP present on the plate. The results of this assay, as shown in
Fig. 5A, indicated firstly that pdd-ASP is unable to inhibit antibod-
ies from binding to the ndd-ASP. In addition, results show that
there was a variation in the specificity of the antibodies induced
in the different animals and that the antibodies present in the
non-protected animal showed the lowest specificity toward ndd-
ASP (Fig. 5B). Such a potential relationship was not observed for
cellular proliferation or antibody levels (results not shown).
A B
C D
Fig. 3. Systemic cellular responses following vaccination with native (n) and recombinant (p) dd-ASP vaccines. (A) During the vaccination period, peripheral blood
mononuclear cells (PBMCs) were isolated weekly, re-stimulated with either medium alone or the antigen used in the vaccine formulation, and the proliferation was
determined based on H-thymidine (3HT) incorporation. The graph shows the mean stimulation index ± S.E.M. for all vaccinated groups (n = 4), where the arrows indicate the
time points at which the animals were immunised. (B-D) Seven weeks after the first vaccination, PBMCs from all groups were stimulated for 5 days with medium or the
vaccine antigen, stained with Paul Karl Horan (PKH) to determine the proliferation with flow cytometry. The mean proliferation indices (PI) ± S.E.M of (B) QuilA Control
(n = 4), (C) pdd-ASP+QuilA (n = 4), and (D) ndd-ASP+QuilA (n = 4) vaccinated animals were calculated and compared with those of the control group. Statistically significant
differences are indicated with *(P  0.05), **(P  0.005).
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Similar to our previous findings (Vlaminck et al., 2015), vaccina-
tion with the native antigens (ndd-ASP) provided protection
against an experimental infection with C. oncophora. Inducing a
protective response with recombinant antigens has proven to be
extremely challenging for most of the anthelmintic vaccines tested
to date (Geldhof et al., 2007; Gonzalez-Hernandez et al., 2016). The
present study shows that this is also the case for the dd-ASP
vaccine against C. oncophora, as vaccination of calves with a
Pichia-produced version of the antigen (pdd-ASP) did not confer
any protection.
Previous studies on vaccine-induced immunity using the native
antigen against C. oncophora revealed the induction of a strong
antigen-specific cellular response in the small intestinal mucosa,
mainly characterized by the presence of antigen-specific ab- and
cd-T cells (Van Meulder et al., 2015). In line with this, the present
study demonstrates that vaccination of calves with ndd-ASP
+QuilA, but not with pdd-ASP+QuilA or QuilA alone, resulted in
an increased systemic memory response from the second vaccina-
tion onwards, which was characterized by the induction of
antigen-specific CD4-T cell proliferation. Although proliferation of
almost all cell populations could be detected for all groups in themesenteric LNs, the magnitude of this response, and more specifi-
cally of the CD4-T cell population, was higher in animals vacci-
nated with the native antigen. These results not only agree with
the findings of Van Meulder et al. (2015), but also resemble the
naturally acquired immunity to C. oncophora where an augmented
CD4-T cell frequency has been observed both systemically and at
the site of infection (Kanobana et al., 2003).
While immunity against helminth infections has been com-
monly associated with a Th2 response, the production of both IL-
4 and IFNc by mesenteric lymphocytes in all groups after re-
stimulation with ndd-ASP suggests a combined Th1/Th2 type
response. The observation of a mixed Th1/Th2 response against a
helminthic infection is not novel and has been extensively docu-
mented for other helminth species such as Fasciola hepatica
(Moreau et al., 2010), Trichinella spiralis (Ilic et al., 2011) and
Ostertagia ostertagi (Mihi et al., 2014).
In terms of humoral responses, the overall results indicated that
both native and recombinant vaccines induce the production of
antigen-specific IgG1, IgG2 and IgA antibodies. Nonetheless, inhibi-
tion ELISAs for all isotypes showed that the antibodies induced by
the ndd-ASP preferentially bind to the ndd-ASP and not to the
recombinantly produced version of the antigen (pdd-ASP), and vice
versa (data not shown). Whether this difference in antibody
Fig. 4. Mucosal cellular responses following vaccination with native (n) and recombinant (p) dd-ASP vaccines. At the time of necropsy, mononuclear cells (MNCs) were
isolated from the small intestinal lymph nodes and their proliferative capacity was evaluated after in vitro stimulation with ndd-ASP. Mean n-fold proliferation index (PI) ± S.
E.M, is shown individually for (A) Control (n = 4), (B) ndd-ASP+QuilA (n = 4) and (C) pdd-ASP+QuilA (n = 4) vaccinated animals. (D) Additionally, n-fold PI between all groups
after ndd-ASP stimulation were compared and are shown as mean ± S.E.M. Supernatants of the previous cultures were collected and the production of (E) IL-4 and (F) IFNc
were determined. Both graphs show the mean OD of either IL-4 or IFNc from medium or antigen-stimulated supernatants for each group (n = 4) ± S.E.M. Statistically
significant differences are indicated with *(P  0.05).
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Fig. 5. Correlation between protection and antibody specificity. Small intestinal extracts from animals vaccinated with native (n)dd-ASP+QuilA in study 2 were individually
tested in an inhibition ELISA (iELISA) by pre-incubation with recombinant (p)dd-ASP and later evaluation on an ndd-ASP coated plate. (A) The graph shows the individual
percentage (%) of recognition for each animal. (B) Correlation between cumulative faecal egg count (cumFEC) values and antibody percentage of recognition in the animals
vaccinated with ndd-ASP+QuilA.
48 A. González-Hernández et al. / International Journal for Parasitology 48 (2018) 41–49specificity is important in conferring protection is still unclear.
However, it is interesting to note that the only animal with high
cumFEC from the ndd-ASP vaccinated group raised antibodies with
the lowest specificity towards ndd-ASP, indicating the existence of
a negative correlation between antibody specificity and parasito-
logical parameters. This suggests an important role for antibodies
in the protective immune response, an observation that has also
been previously made for naturally acquired and vaccine-induced
immunity against C. oncophora (Kanobana et al., 2001; Van
Meulder et al., 2015).
Overall, the observation that both cellular and humoral
responses differ between animals vaccinated with either the native
or the recombinant form of the dd-ASP antigen are in line with our
previous observations on vaccine-induced immunity against O.
ostertagi (Gonzalez-Hernandez et al., 2016). This differential
immune recognition is possibly caused by differences between
native and recombinant proteins in terms of protein conformation
and/or the associated glycan structures. ASPs belong to the
cysteine-rich secretory/antigen 5/pathogenesis-related 1 (CAP)
superfamily and have been suggested to play a role in immune
evasion, although their exact biological functions remain
unknown. As the name itself suggests, proteins belonging to this
family are rich in cysteine residues that form several disulphide
bridges, resulting in a highly conserved a-b-a-sandwich structure
(Gibbs et al., 2008). The exact constitution of these disulphide
bonds has only been obtained based on three-dimensional crystal-
lographic data from recombinantly expressed material (Asojo,
2011; Borloo et al., 2013b), and whether these bridges are actually
present in the native ASPs remains unclear. However, what seems
evident is that protein folding is essential for mounting of a proper
immune response, as demonstrated by the abolition of all vaccine-
induced immune responses (both cellular and humoral) when vac-
cinating animals with an unfolded version of native O. ostertagi
ASP1 protein (Gonzalez-Hernandez et al., 2016). In addition, struc-
tural analysis has revealed differences in the glycans present on the
native and recombinant versions of the dd-ASP antigen (unpub-
lished data). Potentially these differences influence the immuno-
genicity of the antigens. Therefore, further studies with non-
glycosylated forms of the antigens are necessary to provide further
insights on the importance of these glycans.
Taken together, the outcome of the present study shows that
vaccination of calves with a protective ndd-ASP+QuilA vaccine,
but not with its recombinant counterpart, results in a strong cellu-
lar memory response mainly characterized by the presence of
antigen-specific CD4-T cells in both blood and intestinal mucosa.
Although both ndd-ASP and pdd-ASP-based vaccines inducedsimilar levels of antibodies, the specificity of the antibodies raised
by both antigens clearly differed. The possible structural differ-
ences that impede the recombinant vaccine to mount a protective
immune response remain unknown and form the basis of our cur-
rent research.
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